LMK Servicos Medicos SS

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Sjögren's disease3 trials
• COPD2 trials
• Lupus (SLE)2 trials
• Dermatomyositis and polymyositis (myositis)1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Amgen5 trials
• Hoffmann-La Roche2 trials
• Bristol-Myers Squibb1 trial

Running trials

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Bristol-Myers Squibb· Source

  Contact: Mauro Keiserman, Site 0016

• Recruiting

  A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  NCT06747949· Phase 3· Amgen· Source

• Active, not recruiting

  A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

  NCT06245408· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM)

  NCT05669014· Phase 2· Amgen· Source

• Terminated

  Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

  NCT05540665· Phase 2· Amgen· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source